Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 264 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment Adding Epcoritamab to Lenalidomide and Rituximab Results in Higher Response Rate and Longer PFS in Patients with Relapsed or Refractory Follicular Lymphoma MOST POPULAR PET Positivity After Two Cycles of ABVD Is Associated with a... November 22, 2023 ESMO Award for Immuno-Oncology 2025 Recipient Announced November 4, 2025 ¿Qué deben saber las personas con cáncer sobre el consumo de... January 11, 2022 Coronavirus y COVID-19: Qué deben saber las personas con cáncer June 24, 2020 Load more HOT NEWS Navigating Life During and After Cancer As a Young Adult: A... Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term... A New Era of Early Cancer Detection With Blood Test May... Trastuzumab Deruxtecan Demonstrates Durable Responses in Patients with Previously Treated HER2-mutated...
